Effective April 10, 2023, masking is optional in all NYOH sites for patients and employees.

Clinical Trials & Research

21386 - Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01

Disease Types: Colon,  Colorectal,&nbs

Available at: {clinical_trial_location backspace="7"}21386 - Ph2 RO7198457 CRC ctDNA+ Post Resection, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}